Innovation Pharmaceuticals Inc. IPIX
We take great care to ensure that the data presented and summarized in this overview for Innovation Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IPIX
Top Purchases
Top Sells
About IPIX
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Insider Transactions at IPIX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2020
|
Leo Ehrlich CEO and Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
7,835,002
-100.0%
|
$0
$0.21 P/Share
|
|
Sep 11
2020
|
Jane A. Harness Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
58,394
+19.28%
|
-
|
|
Sep 11
2020
|
Jane A. Harness Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
21,606
-10.41%
|
-
|
|
Feb 23
2020
|
Barry A Schechter |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+40.0%
|
-
|
|
Feb 23
2020
|
Zorik Spektor |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+48.78%
|
-
|
|
Feb 23
2020
|
Leo Ehrlich CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+6.0%
|
-
|
|
Sep 01
2019
|
Jane A. Harness Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
58,394
+21.95%
|
-
|
|
Sep 01
2017
|
Jane A. Harness Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,000
-0.67%
|
-
|